How to perform and interpret provocative testing for the diagnosis of brugada syndrome, long-QT syndrome, and catecholaminergic polymorphic ventricular tachycardia

Circulation: Arrhythmia and Electrophysiology

Volumn 4, Issue 6, 2011, Pages 958-964

  Obeyesekere, Manoj N ^a   Klein, George J ^a   Modi, Simon ^a   Leong Sit, Peter ^a   Gula, Lorne J ^a   Yee, Raymond ^a   Skanes, Allan C ^a   Krahn, Andrew D ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Brugada syndrome; Catecholaminergic polymorphic ventricular tachycardia; Long QT syndrome

Indexed keywords

ADENOSINE; ADRENALIN; AJMALINE; FLECAINIDE; PILSICAINIDE; PROCAINAMIDE; ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIARRHYTHMIC AGENT; DIAGNOSTIC AGENT;

BRUGADA SYNDROME; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; ELECTROCARDIOGRAM; HUMAN; LONG QT SYNDROME; PRIORITY JOURNAL; PROVOCATION TEST; REVIEW; ACTION POTENTIAL; CONVALESCENCE; ELECTROCARDIOGRAPHY; EXERCISE TEST; HEART MUSCLE CONDUCTION SYSTEM; HEART RATE; HEART VENTRICLE TACHYCARDIA; PATHOPHYSIOLOGY; PREDICTIVE VALUE; TIME;

ACTION POTENTIALS; ADRENERGIC AGONISTS; ANTI-ARRHYTHMIA AGENTS; BRUGADA SYNDROME; ELECTROCARDIOGRAPHY; EXERCISE TEST; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS; LONG QT SYNDROME; PREDICTIVE VALUE OF TESTS; RECOVERY OF FUNCTION; TACHYCARDIA, VENTRICULAR; TIME FACTORS;

EID: 84857133278     PISSN: 19413149     EISSN: 19413084     Source Type: Journal    
DOI: 10.1161/CIRCEP.111.965947     Document Type: Review

References (44)

1. Priori SG, Aliot E, Blomstrom-Lundqvist C, Bossaert L, Breithardt G, Brugada P, Camm JA, Cappato R, Cobbe SM, Di MC, Maron BJ, McKenna WJ, Pedersen AK, Ravens U, Schwartz PJ, Trusz-Gluza M, Vardas P, Wellens HJ, Zipes DP. Task Force on Sudden Cardiac Death, European Society of Cardiology. Europace. 2002;4:3-18. (Pubitemid 36124388)
2. Krahn AD, Healey JS, Chauhan V, Birnie DH, Simpson CS, Champagne J, Gardner M, Sanatani S, Exner DV, Klein GJ, Yee R, Skanes AC, Gula LJ, Gollob MH. Systematic assessment of patients with unexplained cardiac arrest: Cardiac Arrest Survivors With Preserved Ejection Fraction Registry (CASPER). Circulation. 2009;120:278-285.
3. Vyas H, Hejlik J, Ackerman MJ. Epinephrine QT stress testing in the evaluation of congenital long-QT syndrome: diagnostic accuracy of the paradoxical QT response. Circulation. 2006;113:1385-1392. (Pubitemid 43739434)
4. Hofman N, Wilde AA, Kaab S, van Langen IM, Tanck MW, Mannens MM, Hinterseer M, Beckmann BM, Tan HL. Diagnostic criteria for congenital long QT syndrome in the era of molecular genetics: do we need a scoring system? Eur Heart J. 2007;28:575-580. (Pubitemid 47355496)
5. Keating M, Atkinson D, Dunn C, Timothy K, Vincent GM, Leppert M. Linkage of a cardiac arrhythmia, the long QT syndrome, and the Harvey ras-1 gene. Science. 1991;252:704-706. (Pubitemid 21916997)
6. Viskin S, Postema PG, Bhuiyan ZA, Rosso R, Kalman JM, Vohra JK, Guevara-Valdivia ME, Marquez MF, Kogan E, Belhassen B, Glikson M, Strasberg B, Antzelevitch C, Wilde AA. The response of the QT interval to the brief tachycardia provoked by standing: a bedside test for diagnosing long QT syndrome. J Am Coll Cardiol. 2010;55:1955-1961.
7. Chattha IS, Sy RW, Yee R, Gula LJ, Skanes AC, Klein GJ, Bennett MT, Krahn AD. Utility of the recovery electrocardiogram after exercise: a novel indicator for the diagnosis and genotyping of long QT syndrome? Heart Rhythm. 2010;7:906-911.
8. Sy RW, Chattha IS, Klein GJ, Gula LJ, Skanes AC, Yee R, Bennett MT, Krahn AD. Repolarization dynamics during exercise discriminate between LQT1 and LQT2 genotypes. J Cardiovasc Electrophysiol. 2010; 21:1242-1246.
9. Krahn AD, Klein GJ, Yee R. Hysteresis of the RT interval with exercise: a new marker for the long-QT syndrome? Circulation. 1997;96: 1551-1556. (Pubitemid 27375351)
10. Wong JA, Gula LJ, Klein GJ, Yee R, Skanes AC, Krahn AD. Utility of treadmill testing in identification and genotype prediction in long-QT syndrome. Circ Arrhythm Electrophysiol. 2010;3:120-125.
11. Shimizu W, Noda T, Takaki H, Nagaya N, Satomi K, Kurita T, Suyama K, Aihara N, Sunagawa K, Echigo S, Miyamoto Y, Yoshimasa Y, Nakamura K, Ohe T, Towbin JA, Priori SG, Kamakura S. Diagnostic value of epinephrine test for genotyping LQT1, LQT2, and LQT3 forms of congenital long QT syndrome. Heart Rhythm. 2004;1:276-283. (Pubitemid 39549754)
12. Ackerman MJ, Khositseth A, Tester DJ, Hejlik JB, Shen WK, Porter CB. Epinephrine-induced QT interval prolongation: a gene-specific paradoxical response in congenital long QT syndrome. Mayo Clin Proc. 2002;77:413-421. (Pubitemid 34465148)
13. Kaufman ES, Gorodeski EZ, Dettmer MM, Dikshteyn M. Use of autonomic maneuvers to probe phenotype/genotype discordance in congenital long QT syndrome. Am J Cardiol. 2005;96:1425-1430. (Pubitemid 41566626)
14. Shimizu W, Noda T, Takaki H, Kurita T, Nagaya N, Satomi K, Suyama K, Aihara N, Kamakura S, Sunagawa K, Echigo S, Nakamura K, Ohe T, Towbin JA, Napolitano C, Priori SG. Epinephrine unmasks latent mutation carriers with LQT1 form of congenital long-QT syndrome. J Am Coll Cardiol. 2003;41:633-642. (Pubitemid 36223330)
15. Krahn AD, Gollob M, Yee R, Gula LJ, Skanes AC, Walker BD, Klein GJ. Diagnosis of unexplained cardiac arrest: role of adrenaline and procainamide infusion. Circulation. 2005;112:2228-2234. (Pubitemid 41464564)
16. Viskin S, Rosso R, Rogowski O, Belhassen B, Levitas A, Wagshal A, Katz A, Fourey D, Zeltser D, Oliva A, Pollevick GD, Antzelevitch C, Rozovski U. Provocation of sudden heart rate oscillation with adenosine exposes abnormal QT responses in patients with long QT syndrome: a bedside test for diagnosing long QT syndrome. Eur Heart J. 2006;27: 469-475. (Pubitemid 43209174)
17. Kaufman ES, Priori SG, Napolitano C, Schwartz PJ, Iyengar S, Elston RC, Schnell AH, Gorodeski EZ, Rammohan G, Bahhur NO, Connuck D, Verrilli L, Rosenbaum DS, Brown AM. Electrocardiographic prediction of abnormal genotype in congenital long QT syndrome: experience in 101 related family members. J Cardiovasc Electrophysiol. 2001;12:455-461. (Pubitemid 32324661)
18. Mauriello DA, Johnson JN, Ackerman MJ. Holter monitoring in the evaluation of congenital long QT syndrome. Pacing Clin Electrophysiol. In press.
19. Neyroud N, Maison-Blanche P, Denjoy I, Chevret S, Donger C, Dausse E, Fayn J, Badilini F, Menhabi N, Schwartz K, Guicheney P, Coumel P. Diagnostic performance of QT interval variables from 24-h electrocardiography in the long QT syndrome. Eur Heart J. 1998;19:158-165. (Pubitemid 28112313)
20. Nemec J, Buncova M, Bulkova V, Hejlik J, Winter B, Shen WK, Ackerman MJ. Heart rate dependence of the QT interval duration: differences among congenital long QT syndrome subtypes. J Cardiovasc Electrophysiol. 2004;15:550-556. (Pubitemid 38621906)
21. Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc DD, Coumel P. Catecholaminergic polymorphic ventricular tachycardia in children: a 7-year follow-up of 21 patients. Circulation. 1995;91:1512-1519.
22. Cerrone M, Noujaim SF, Tolkacheva EG, Talkachou A, O'Connell R, Berenfeld O, Anumonwo J, Pandit SV, Vikstrom K, Napolitano C, Priori SG, Jalife J. Arrhythmogenic mechanisms in a mouse model of catecholaminergic polymorphic ventricular tachycardia. Circ Res. 2007;101: 1039-1048. (Pubitemid 350084981)
23. Wehrens XH. The molecular basis of catecholaminergic polymorphic ventricular tachycardia: what are the different hypotheses regarding mechanisms? Heart Rhythm. 2007;4:794-797. (Pubitemid 46840325)
24. Liu N, Colombi B, Memmi M, Zissimopoulos S, Rizzi N, Negri S, Imbriani M, Napolitano C, Lai FA, Priori SG. Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model. Circ Res. 2006;99:292-298. (Pubitemid 44174937)
25. Sy RW, Gollob MH, Klein GJ, Yee R, Skanes AC, Gula LJ, Leong-Sit P, Gow RM, Green MS, Birnie DH, Krahn AD. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2011;8:864-871.
26. Hayashi M, Denjoy I, Extramiana F, Maltret A, Buisson NR, Lupoglazoff JM, Klug D, Takatsuki S, Villain E, Kamblock J, Messali A, Guicheney P, Lunardi J, Leenhardt A. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation. 2009;119:2426-2434.
27. Haugaa KH, Leren IS, Berge KE, Bathen J, Loennechen JP, Anfinsen OG, Fruh A, Edvardsen T, Kongsgard E, Leren TP, Amlie JP. High prevalence of exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia mutation-positive family members diagnosed by cascade genetic screening. Europace. 2010;12:417-423.
28. Bauce B, Rampazzo A, Basso C, Bagattin A, Daliento L, Tiso N, Turrini P, Thiene G, Danieli GA, Nava A. Screening for ryanodine receptor type 2 mutations in families with effort-induced polymorphic ventricular arrhythmias and sudden death: early diagnosis of asymptomatic carriers. J Am Coll Cardiol. 2002;40:341-349. (Pubitemid 34756298)
29. van der Werf C, Kannankeril PJ, Sacher F, Krahn AD, Viskin S, Leenhardt A, Shimizu W, Sumitomo N, Fish FA, Bhuiyan ZA, Willems AR, van der Veen MJ, Watanabe H, Laborderie J, Haissaguerre M, Knollmann BC, Wilde AA. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol. 2011;57:2244-2254.
30. Rosso R, Kalman JM, Rogowski O, Diamant S, Birger A, Biner S, Belhassen B, Viskin S. Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2007;4:1149-1154. (Pubitemid 47324118)
31. Veltmann C, Schimpf R, Echternach C, Eckardt L, Kuschyk J, Streitner F, Spehl S, Borggrefe M, Wolpert C. A prospective study on spontaneous fluctuations between diagnostic and non-diagnostic ECGs in Brugada syndrome: implications for correct phenotyping and risk stratification. Eur Heart J. 2006;27:2544-2552. (Pubitemid 44627298)
32. Priori SG, Napolitano C, Gasparini M, Pappone C, Della Bella P, Giordano U, Bloise R, Giustetto C, De Nardis R, Grillo M, Ronchetti E, Faggiano G, Nastoli J. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation. 2002;105:1342-1347. (Pubitemid 34260426)
33. Miyazaki T, Mitamura H, Miyoshi S, Soejima K, Aizawa Y, Ogawa S. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol. 1996;27: 1061-1070. (Pubitemid 26119611)
34. Brugada J, Brugada R, Antzelevitch C, Towbin J, Nademanee K, Brugada P. Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. Circulation. 2002;105:73-78. (Pubitemid 34049145)
35. Priori SG, Napolitano C, Gasparini M, Pappone C, Della Bella P, Brignole M, Giordano U, Giovannini T, Menozzi C, Bloise R, Crotti L, Terreni L, Schwartz PJ. Clinical and genetic heterogeneity of right bundle branch block and ST-segment elevation syndrome: a prospective evaluation of 52 families. Circulation. 2000;102:2509-2515.
36. Probst V, Veltmann C, Eckardt L, Meregalli PG, Gaita F, Tan HL, Babuty D, Sacher F, Giustetto C, Schulze-Bahr E, Borggrefe M, Haissaguerre M, Mabo P, Le Marec H, Wolpert C, Wilde AA. Long-term prognosis of patients diagnosed with Brugada syndrome: results from the FINGER Brugada Syndrome Registry. Circulation. 2010;121:635-643.
37. Miyamoto K, Yokokawa M, Tanaka K, Nagai T, Okamura H, Noda T, Satomi K, Suyama K, Kurita T, Aihara N, Kamakura S, Shimizu W. Diagnostic and prognostic value of a type 1 Brugada electrocardiogram at higher (third or second) V1 to V2 recording in men with Brugada syndrome. Am J Cardiol. 2007;99:53-57. (Pubitemid 44969340)
38. Batchvarov VN, Govindan M, Camm AJ, Behr ER. Significance of QRS prolongation during diagnostic ajmaline test in patients with suspected Brugada syndrome. Heart Rhythm. 2009;6:625-631.
39. Nishizaki M, Sakurada H, Yamawake N, Ueda-Tatsumoto A, Hiraoka M. Low risk for arrhythmic events in asymptomatic patients with druginduced type 1 ECG: do patients with drug-induced Brugada type ECG have poor prognosis? Circ J. 2010;74:2464-2473.
40. Shimizu W, Antzelevitch C, Suyama K, Kurita T, Taguchi A, Aihara N, Takaki H, Sunagawa K, Kamakura S. Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000;11:1320-1329. (Pubitemid 32016854)
41. Wolpert C, Echternach C, Veltmann C, Antzelevitch C, Thomas GP, Spehl S, Streitner F, Kuschyk J, Schimpf R, Haase KK, Borggrefe M. Intravenous drug challenge using flecainide and ajmaline in patients with Brugada syndrome. Heart Rhythm. 2005;2:254-260. (Pubitemid 40309821)
42. Meregalli PG, Ruijter JM, Hofman N, Bezzina CR, Wilde AA, Tan HL. Diagnostic value of flecainide testing in unmasking SCN5A-related Brugada syndrome. J Cardiovasc Electrophysiol. 2006;17:857-864. (Pubitemid 44079745)
43. Hong K, Brugada J, Oliva A, Berruezo-Sanchez A, Potenza D, Pollevick GD, Guerchicoff A, Matsuo K, Burashnikov E, Dumaine R, Towbin JA, Nesterenko V, Brugada P, Antzelevitch C, Brugada R. Value of electrocardiographic parameters and Ajmaline test in the diagnosis of Brugada syndrome caused by SCN5A mutations. Circulation. 2004;110: 3023-3027. (Pubitemid 39491993)
44. Brugada R, Brugada J, Antzelevitch C, Kirsch GE, Potenza D, Towbin JA, Brugada P. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation. 2000;101:510-515. (Pubitemid 30080865)